Obstructive sleep apnea syndrome is a common and potentially serious comorbidity in people with diabetes and obesity. John Wilding highlights what you need to know about the condition.
Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.
Findings from a dose-ranging phase II trial published in The Lancet suggest that semaglutide, in combination with lifestyle intervention, may aid weight loss in people with obesity who do not have diabetes.
A meta-analysis shows that although medications and lifestyle changes can both reduce the risk for type 2 diabetes in high-risk patients, only lifestyle modifications have a sustained effect.
The National Institute For Health and Care Excellence has issued an evidence summary to support use of the glucagon-like peptide-1 receptor agonist liraglutide in obese and overweight individuals with risk factors, such as dysglycemia.
A patient affected by obesity discusses her experience of living with the disease and using many different weight loss approaches until finding a lifestyle program that was appropriate for her metabolism.
Taking the glucagon-like peptide-1 receptor agonist liraglutide does not increase patients’ risk for acute pancreatitis during more than 3 years of treatment, show two reports analyzing the LEADER and SCALE trials.
Targeting obese patients for weight-loss therapy according to their cardiometabolic status could much improve its effectiveness for diabetes prevention, say researchers.